Best-in-class treatment for Wilson’s disease

Orphalan was incorporated in 2011 to reposition drugs in orphan diseases by exploiting untapped academic research and existing clinical data. The lead indication is Wilson’s disease which results from the toxic accumulation of copper in the body.

Current treatments are not satisfactory due to harmful side effects or complex drug handling requirements. Orphalan has developed a best in class molecule to address this unmet medical need.

CEO  Naseem Amin

Advent Contact   Alain Huriez

Advent was the sole institutional investor in the Series A in 2015.
Private Companies
2 May 2022 in Orphalan, Press Release, Private Companies

Orphalan announces FDA approval of Cuvrior™ for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine

Press Release.   Paris, France 2 May 2022 – Orphalan SA (“Orphalan” or “the Company”), an international orphan drug development and commercialisation company, today announces approval of Cuvrior™, a new…
Read More
2 September 2021 in Orphalan, Press Release, Private Companies

Orphalan announces FDA acceptance for filing of New Drug Application (NDA) for trientine tetrahydrochloride (TETA 4HCl) for the treatment of Wilson’s Disease

Press Release.   NDA supported by positive data from Phase 3 CHELATE clinical trial TETA 4-HCl previously granted Orphan Drug Designation for first-line treatment of Wilson’s Disease Paris, France –…
Read More